Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients

BACKGROUND: In this study, we investigated the ability of prostate-specific antigen (PSA) 12 months after (nPSA12) external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) to predict biochemical recurrence-free survival (BRFS), overall survival (OS), and prostate cancer-spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cetin, Ilknur Alsan, Akay, Sıtkı Utku, Sengoz, Meric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664688/
https://www.ncbi.nlm.nih.gov/pubmed/36376849
http://dx.doi.org/10.1186/s12894-022-01125-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664688/
https://www.ncbi.nlm.nih.gov/pubmed/36376849
http://dx.doi.org/10.1186/s12894-022-01125-1

Ejemplares similares